Results 191 to 200 of about 546,892 (350)

Holistic care in mild upper respiratory tract infections (MURTIs): an approach to individualized care management. [PDF]

open access: yesDrugs Context
Smith A   +6 more
europepmc   +1 more source

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane   +33 more
wiley   +1 more source

The TRIP database showed most Acute Respiratory Infections questions were already addressed by Cochrane reviews [PDF]

open access: yes, 2019
Brassey, Jon   +4 more
core   +1 more source

Relationships of Upper respiratory tract infections and holistic diets and lifestyles in Northeast China. [PDF]

open access: yesBMC Nutr
Wang H   +9 more
europepmc   +1 more source

Pathogen spectrum changes of respiratory tract infections in children in Chaoshan area under the influence of COVID-19

open access: gold, 2021
Chuangxing Lin   +6 more
openalex   +1 more source

Serious Infections in Offspring Exposed to Tumour Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability

open access: yesArthritis &Rheumatology, Accepted Article.
Objective We evaluated serious infection risk in offspring exposed to tumour necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011‐2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman   +6 more
wiley   +1 more source

Therapeutic efficacy of aerosolized moxifloxacin in respiratory tract infection in goats [PDF]

open access: green, 2019
Ravi Shankar Kumar Mandal   +8 more
openalex  

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy